Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem

Study Objective. To compare the pharmacodynamics of two β‐lactams—ceftazidime and meropenem—in healthy subjects versus patients.

[1]  J. Turnidge.  The Pharmacodynamics of β-Lactams , 1998 .

[2]  D. Nicolau,et al.  Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. , 2004, Diagnostic microbiology and infectious disease.

[3]  M. Hutchison,et al.  Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. , 1991, The Journal of antimicrobial chemotherapy.

[4]  T. Fabian,et al.  Intermittent and continuous ceftazidime infusion for critically ill trauma patients. , 2000, American journal of surgery.

[5]  T. Berne,et al.  Pharmacokinetics of meropenem in patients with intra-abdominal infections , 1994, Antimicrobial Agents and Chemotherapy.

[6]  G. Drusano,et al.  Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation: CME REVIEW ARTICLE , 2003, The Pediatric infectious disease journal.

[7]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[8]  A. MacGowan,et al.  The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. , 1995, The Journal of antimicrobial chemotherapy.

[9]  D. Nicolau,et al.  Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa , 2004, Pharmacotherapy.

[10]  B. Ljungberg,et al.  Pharmacokinetics of meropenem in febrile neutropenic patients , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[11]  C. Frei,et al.  Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. , 2004, Clinical therapeutics.

[12]  M. Palazzo,et al.  Altered Pharmacokinetics of Ceftazidime in Critically Ill Patients , 1999, Antimicrobial Agents and Chemotherapy.

[13]  E. Prens,et al.  Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers , 1990, Antimicrobial Agents and Chemotherapy.

[14]  D. Farin,et al.  Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. , 2002, International journal of antimicrobial agents.

[15]  M. Hutchison,et al.  Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  G. Chow.  Tests of equality between sets of coefficients in two linear regressions (econometrics voi 28 , 1960 .

[17]  N. White,et al.  Interactions in vitro between agents used to treat melioidosis. , 1989, The Journal of antimicrobial chemotherapy.

[18]  F. Vallée,et al.  Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin , 1992, Antimicrobial Agents and Chemotherapy.

[19]  R. Bax,et al.  The pharmacokinetics of meropenem in volunteers. , 1989, The Journal of antimicrobial chemotherapy.

[20]  A. Schmitt-Hoffmann,et al.  Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141 , 2004, Antimicrobial Agents and Chemotherapy.

[21]  T. Staudinger,et al.  Continuous infusion versus intermittent administration of meropenem in critically ill patients. , 1999, The Journal of antimicrobial chemotherapy.

[22]  J. Fillastre,et al.  Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment , 1992, Antimicrobial Agents and Chemotherapy.

[23]  D. Nicolau,et al.  Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002 , 2004, Antimicrobial Agents and Chemotherapy.

[24]  T. Oh,et al.  Intermittent bolus dosing of ceftazidime in critically ill patients. , 1997, Journal of Antimicrobial Chemotherapy.

[25]  J. Fillastre,et al.  Pharmacokinetics of ceftazidime in normal and uremic subjects , 1984, Antimicrobial Agents and Chemotherapy.

[26]  T. Schaberg,et al.  Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin , 1996, Antimicrobial agents and chemotherapy.

[27]  D M Grasela,et al.  The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. , 2000, Diagnostic microbiology and infectious disease.

[28]  B. Ljungberg,et al.  Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group. , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[29]  J. Turnidge.  The Pharmacodynamics of b-Lactams , 1998 .

[30]  Ronald N. Jones,et al.  Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. , 2003, Diagnostic microbiology and infectious disease.

[31]  D. Nicolau,et al.  Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem , 2003, Journal of clinical pharmacology.

[32]  G. Drusano,et al.  Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. , 2004, Clinical therapeutics.

[33]  B. Ljungberg,et al.  Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males , 2004, European Journal of Clinical Pharmacology.

[34]  B. Ljungberg,et al.  Pharmacokinetics of ceftazidime in febrile neutropenic patients. , 2001, Scandinavian journal of infectious diseases.

[35]  R. Jones,et al.  Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program , 2003, Antimicrobial Agents and Chemotherapy.